SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VERU

Veru Inc. (NASDAQ:VERU)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.94-$0.17 (-8.06%)
 
Market cap
$33.1M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 11, 1999
Market Cap$33.08M-17.1%
Revenue (ttm)$0-100.0%
Net Income-$13.61M+58.4%
EPS-$0.60+72.9%
Shares Out17.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateApr 28, 2014
Volume247,922
Open$2.13
Previous Close$2.11
Day's Range$1.93 - $2.14
52-Week Range$1.93 - $7.33
Betan/a
AnalystsBuy
Price Target$4.00(+106.19%)
Earnings DateNov 26, 2026

About VERU

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

Address
2916 North Miami Avenue, Miami, FL, 33127, US
Market Cap
33 million
Employees
20
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$4.84K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From VERU’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-8.06%
5 Days
-6.73%
1 Month
-15.28%
6 Months
-17.45%
1 Year
-17.09%

$VERU stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VERU holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VERU's directors and management

Net Shares Purchased by Insiders−2k−1k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VERU Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VERU Revenue by Segment or Geography

VERU's latest filing doesn't break out revenue by segment.

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VERU patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VERU from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VERU

VTIVanguard Morningstar Total Stock Market ETF$841.04K
VXFVanguard Extended Market ETF$346.38K
IWCiShares Micro-Cap ETF$86.69K
STSBiShares Factors US Small Blend Style ETF$2.46K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VERU’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
19.61
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$4.84K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.